Why Patient Understanding is the Most Important Metric You Aren’t Tracking
Aayush Sisodia, MSHI, BDS, Business Analytics Advisor, Pharmacy Analytics Health systems are drowning in metrics. We can tell you how many portal messages were answered within 24 hours, how many patients closed a care gap, and how many clinicians are using ambient AI in their notes. But there is one question our dashboards rarely answer: […]
What doctors won’t tell you about Ozempic side-effects
Whether you like them or not, weight-loss drugs have changed the world. Obesity levels in the US, which had been on the rise for years, are falling. National spend on food has shrunk, fashion outlets are selling fewer XXL-sized clothes and, here in the UK, one supermarket has even launched a ‘nutrient dense’ food range, […]
With GLP-1 & NA Innovations, Langers Juice Sees Functional Future
Backed by a $10 million investment in manufacturing tech, Langers Juice is looking to play a bigger role in the growing functional beverage boom.
Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an increased risk of developing colorectal cancer (CRC). MASLD and CRC share many common risk factors and pathophysiological mechanisms, but an optimal strategy for identifying and managing CRC risk in individuals with […]
Novo Nordisk Rebuilds Its Case as GLP-1 Fears Fade and Valuation Resets
GLP-1 Therapies for Addiction and Mental Health Comorbidities
This narrative review discusses the current landscape of glucagon-like peptide-1 therapies in the context of alcohol and other substance use disorders, mental health considerations, and gaps and opportunities in this field.
Fiber’s comeback: Why snacks are embracing the next functional macro
Fiber is resurging in snacks as interest in gut health, GLP-1 use and clean-label demand grow, pushing brands to rethink functional nutrition beyond protein.
Healthy Returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s
Structure Therapeutics CEO Ray Stevens talked about the biotech’s path forward and his expectations for the future of the booming GLP-1 space.
STAT+: Novo strikes deal for diabetes cell therapies
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’re breaking down some of the key parts of a sweeping new health care bill today. The need-to-know this morning Johnson & Johnson kicked off the fourth-quarter earnings season with in-line profits […]
Beyond the Bald Truth: Rejecting Big Pharma’s GLP-1 Gamble for Natural, Lifelong Health
(NaturalNews) Introduction: The High Cost of Quick FixesIn the frenzied pursuit of rapid weight loss, millions have turned to GLP-1 drugs like Ozempic and Wegovy,…